TABLE 2.
Efficacy of sordarin derivatives against systemic candidiasis in mice
| Compounda (MIC [μg/ml]) | Dose (mg/kg) | No. of survivors/ total no. of mice | Survival (days)b
|
||
|---|---|---|---|---|---|
| Mean ± SE | Median | Range | |||
| Control | 0 /20 | 8.1 ± 0.40 | 8.0 | 5–10 | |
| GM193663 (0.015) | 5 | 0 /10 | 9.8 ± 0.57 | 10.0 | 7–12 |
| 10 | 0 /10 | 12.2 ± 0.57 | 12.0 | 10–15 | |
| 20 | 5 /10 | 21.4 ± 2.74 | 15.0 | 11–30 | |
| 40 | 7 /10 | 25.0 ± 2.42 | 30.0 | 13–30 | |
| GM237354 (0.001) | 5 | 0 /10 | 10.1 ± 0.59 | 11.0 | 7–12 |
| 10 | 5 /10 | 20.6 ± 2.99 | 14.0 | 9–30 | |
| 20 | 9 /10 | 28.4 ± 1.52 | 30.0 | 14–30 | |
| 40 | 10 /10 | 30.0 ± 0.0 | 30.0 | 30–30 | |
a
Sordarin derivatives were administered subcutaneously every 8 h (t.i.d.) for seven consecutive days.
b
P values, comparing survival in treated and control groups by log rank test, were all <0.05.